Corporate Overview February 2026 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. 1 Forward-Looking Statements Certain matters discussed in this presentation are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Without limiting the foregoing, we may, in some cases, use terms such as "predicts," "believes," "potentia ...

Core Viewpoint - BioNTech SE will announce its financial results for Q4 and full year 2025 on March 10, 2026, and will host a conference call and webcast for stakeholders to discuss these results and provide a corporate update [1]. Company Overview - BioNTech is a global next-generation immunotherapy company focused on developing novel therapies for cancer and other serious diseases, utilizing a variety of computational discovery and therapeutic modalities [4]. - The company has a diversified portfolio of oncology product candidates, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies [4]. - BioNTech is also researching and developing multiple mRNA vaccine candidates for various infectious diseases, leveraging its expertise in mRNA development and in-house manufacturing capabilities [4]. - The company has established partnerships with several global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Pfizer, and Genentech, among others [4].

Core Insights - The Growth Stock Forum focuses on identifying attractive growth stocks, particularly in the biotech sector, emphasizing risk/reward situations [1] - The biotech Top Picks of the forum achieved a remarkable increase of 137.6% last year, with a compound annual growth rate (CAGR) of 37.2% since 2017 [1] - The core portfolio, LTGP, has also demonstrated strong performance with a mid-20s CAGR as of February 20, 2026 [1]

Psyence Group Inc. Enters into Amending Agreement to Extend Amalgamation Timeline with GoldCoast Resource Corp. ELEMENT--[Back to the Newsroom]# Psyence Group Inc. Enters into Amending Agreement to Extend Amalgamation Timeline with GoldCoast Resource Corp.TORONTO, ON / [ACCESS Newswire]/ February 24, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that it has entered into an amending agreement (the "Amending Agreement") dated February 24, 2026 with GoldCoast Resource Corp. ("Gold ...

Core Insights - The weight-loss drug market is rapidly growing, with investment opportunities in established companies like Eli Lilly and Novo Nordisk, as well as smaller biotech firms like Viking Therapeutics [1][2] Company Overview - Viking Therapeutics is focusing on developing VK2735, a GLP-1 medicine currently in phase 3 clinical trials, which increases the likelihood of approval compared to candidates in earlier stages [5][10] - The company is exploring both subcutaneous and oral formulations of VK2735, aiming to address the challenge of maintaining weight loss after treatment [7][8] Market Potential - As of mid-2025, there are 277 obesity-drug candidates in development, but most are unlikely to receive approval, highlighting the competitive nature of the market [4] - Viking's strong mid-stage results for VK2735 position it favorably within this competitive landscape, potentially leading to significant financial success and stock market returns over the next decade [8] Investment Considerations - Investing in Viking Therapeutics is considered riskier but may offer higher upside potential, with a suggested investment of $5,000 for those with above-average risk tolerance [2][10] - The success of VK2735 in phase 3 trials is critical for the company's future market impact and stock performance [10]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Mereo BioPharma Group plc due to alleged violations of federal securities laws related to misleading statements about clinical trial results [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Mereo BioPharma to contact them to discuss their legal options [1]. - There is a deadline of April 6, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Mereo [2][7]. Group 2: Clinical Trial Results - Mereo announced that two Phase 3 studies of setrusumab failed to meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [5]. - Despite the failure to meet primary endpoints, the trials showed statistically significant improvements in bone mineral density on secondary endpoints, and no new safety concerns were identified [5]. Group 3: Market Reaction - Following the announcement of the failed trials, Mereo's stock price fell by $2.02 per share, or 87.64%, closing at $0.28 per share on December 29, 2025 [6].

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF†) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) ("Corcept†or the "Company†), if they purchased or otherwise acquired the Company's shares between October 31, 2024 and December 30, 2025, inclusive (t ...

Vir Biotechnology (NasdaqGS:VIR) Q4 2025 Earnings call February 23, 2026 05:30 PM ET Company ParticipantsJason O'Byrne - EVP and Interim CFOJohann de Bono - Regius Professor of Cancer ResearchJosh Schimmer - Senior Managing DirectorKiki Patel - Head of Investor RelationsMarianne De Backer - CEO and DirectorMark Eisner - EVP and Chief Medical OfficerPatrick Trucchio - Managing Director of Equity ResearchSean McCutcheon - VP of Biotechnology Equity ResearchConference Call ParticipantsAlec Stranahan - VP and S ...

Vir Biotechnology (NasdaqGS:VIR) Q4 2025 Earnings call February 23, 2026 05:30 PM ET Company ParticipantsJason O'Byrne - EVP and Interim CFOJohann de Bono - Regius Professor of Cancer ResearchJosh Schimmer - Senior Managing DirectorKiki Patel - Head of Investor RelationsMarianne De Backer - CEO and DirectorMark Eisner - EVP and Chief Medical OfficerPatrick Trucchio - Managing Director of Equity ResearchSean McCutcheon - VP of Biotechnology Equity ResearchConference Call ParticipantsAlec Stranahan - VP and S ...

Financial Data and Key Metrics Changes - R&D expenses for 2025 were $456 million, a decrease of $51 million or 10% from $507 million in 2024 [42] - SG&A expenses decreased to $92 million in 2025 from $119 million in the prior year, representing a 23% reduction [42] - The net loss for 2025 was $438 million, compared to $522 million in 2024 [43] - The company started 2026 with approximately $782 million in cash, cash equivalents, and investments, not including the upfront cash and equity from the Astellas collaboration [43] Business Line Data and Key Metrics Changes - The collaboration with Astellas is focused on the development and commercialization of VIR-5500, a T-cell engager for prostate cancer [6][12] - The total potential in combined upfront and milestone payments from the collaboration is $1.7 billion, with a 50/50 profit-sharing arrangement in the U.S. [13][41] Market Data and Key Metrics Changes - Prostate cancer represents a significant global health burden, with 1 in 8 men diagnosed in their lifetime and a five-year survival rate of only 30% for patients with metastatic castration-resistant prostate cancer (mCRPC) [9] - There are approximately 100,000 mCRPC patients in the U.S. and Europe, indicating a substantial unmet need for novel treatment solutions [9] Company Strategy and Development Direction - The strategic collaboration with Astellas aims to accelerate the development of VIR-5500 across various lines of prostate cancer, unlocking significant market opportunities [7][12] - The company plans to initiate dose expansion cohorts in late-line mCRPC monotherapy and combinations in the second quarter of 2026 [38][61] - The PRO-XTEN platform is expected to enable the development of next-generation T-cell engagers for solid tumors, with plans for further preclinical programs [44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of VIR-5500, highlighting its favorable safety and efficacy profile based on emerging Phase I data [6][18] - The collaboration with Astellas is seen as a key factor in maximizing the potential of VIR-5500 and expanding the company's pipeline [44][45] Other Important Information - The Phase I clinical study of VIR-5500 showed a favorable safety profile with no observed dose-limiting toxicities and limited cytokine release syndrome [30][32] - The company is positioned to transition into expansion cohorts and plans to continue dose optimization to meet FDA requirements [38][39] Q&A Session Summary Question: Can you comment on the range of PSA responses seen by prior line of therapies, particularly with regard to prior radiotherapy? - Management noted strong PSA responses, particularly at higher doses, but specific effects of prior treatments on PSA responses were difficult to determine due to the heavily pretreated population [52][54] Question: What are the next steps before moving to Phase 3 with Astellas? - The company plans to initiate expansion cohorts in Q2 2026, focusing on late-line mCRPC as a monotherapy and combinations with other therapies [60][61] Question: How does the larger cohort of patients evaluated on VIR-5500 evolve the thinking about its positioning within the treatment paradigm? - Management indicated plans to address a broad range of patients, including late-line mCRPC and combinations, highlighting the high unmet need in these populations [66] Question: Can you provide more information on the go-forward dose? - The go-forward dose is expected to be in the range of 3,000 to 3,500 micrograms per kilogram, with compelling dose-response data observed [76][77]